Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Accounts Payables (2016 - 2025)

Ascendis Pharma A (ASND) has disclosed Accounts Payables for 10 consecutive years, with $105.5 million as the latest value for Q4 2025.

  • Quarterly Accounts Payables rose 2.45% to $105.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $105.5 million through Dec 2025, up 2.45% year-over-year, with the annual reading at $105.5 million for FY2025, 2.45% up from the prior year.
  • Accounts Payables hit $105.5 million in Q4 2025 for Ascendis Pharma A, up from $103.0 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $105.5 million in Q4 2025 to a low of $68.0 million in Q4 2021.
  • Historically, Accounts Payables has averaged $96.3 million across 5 years, with a median of $103.0 million in 2024.
  • Biggest five-year swings in Accounts Payables: soared 160.35% in 2021 and later fell 1.29% in 2023.
  • Year by year, Accounts Payables stood at $68.0 million in 2021, then skyrocketed by 51.65% to $103.1 million in 2022, then fell by 1.29% to $101.7 million in 2023, then increased by 1.24% to $103.0 million in 2024, then grew by 2.45% to $105.5 million in 2025.
  • Business Quant data shows Accounts Payables for ASND at $105.5 million in Q4 2025, $103.0 million in Q4 2024, and $101.7 million in Q4 2023.